A contingent value right (CVR) is a right issued to the shareholders of a company being acquired, entitling them to an additional payment if a specified event occurs after the deal closes. Typical triggers are a drug approval, a sales milestone or a share-price level by a set date. CVRs help a buyer and seller agree on a price when they disagree about an uncertain future, much like earn-out consideration in private deals, and they form part of the payment in mergers and acquisitions.
CVRs may be listed on a stock exchange, so holders can sell them, or kept non-transferable. They are common in pharmaceutical and biotechnology takeovers; Sanofi issued listed CVRs when it bought Genzyme in 2011. A CVR is a type of contingent liability for the buyer, and its price reflects the odds of the event, which interests traders in merger arbitrage. Many CVRs expire without paying anything.
Ref 1160000320